Accession Number:



Thymine DNA Glycosylase as a Novel Target for Lung Cancer

Descriptive Note:

Technical Report,01 Jul 2018,30 Jun 2019

Corporate Author:

Institute for Cancer Research Philadelphia United States

Personal Author(s):

Report Date:


Pagination or Media Count:



The purpose of this research is to develop novel therapeutics for lung cancer LC based on targeting the dual DNA repair and epigenetic factor Thymine DNA Glycosylase TDG. In principle, inhibiting TDG may both disrupt DNA repair and the cancer epigenetic state of LC cells, thus achieving a therapeutic effect that enhances the actions of existing chemotherapies and is complementary to current epigenetic therapyagents. In the current reporting period, we collected triplicate DNA and RNA samples from control and TDG knockdown A549 and H1299 lung cancer cells, in preparation for methylome and transcriptome studies. We also discovered that cells depleted of TDG have a phenotype of altered genomic stability involving mitotic function, which was completely unpredicted. Based on this discovery, in future experiments, wewill evaluate the cytotoxicity of lung cancer cells treated with first-generation TDG inhibitors, as originally proposed, but in combination with anti-mitotic drugs.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: